Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506151 | 0.90 | P2RX7 (0.39) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1506339 | 0.88 | MAPK1 (0.41) | P2RX7MAPK1TRPV1KCNJ6KCNJ5 | |
| SCHEMBL1506262 | 0.88 | KCNJ6 (0.41) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL15387568 | 0.86 | MAPK1 (0.39) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL10009318 | 0.84 | BRAF (0.42) | P2RX7MAPK1 | |
| SCHEMBL1506198 | 0.84 | MAPK1 (0.38) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1506163 | 0.83 | THRB (0.45) | MAPK1TRPV1 | |
| SCHEMBL1506218 | 0.83 | KCNJ6 (0.40) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1506231 | 0.81 | MAPK1 (0.45) | P2RX7MAPK1 | |
| SCHEMBL10009314 | 0.81 | MAPK1 (0.35) | P2RX7MAPK1KCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| EP-2491024-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033018-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | P2RX7 43/4885MAPK1 1404/4885TRPV1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.